• Users Online: 202
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO THE EDITOR
Year : 2021  |  Volume : 18  |  Issue : 4  |  Page : 441-442

Ototoxicity of chloroquine and hydroxychloroquine: Need for awareness during COVID-19 pandemic


Department of ENT and Head & Neck Surgery, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Guntur, Andhra Pradesh, India

Date of Submission23-Jul-2021
Date of Acceptance01-Sep-2021
Date of Web Publication18-Dec-2021

Correspondence Address:
Satvinder Singh Bakshi
Department of ENT and Head & Neck Surgery, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Guntur 522503, Andhra Pradesh.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/MJBL.MJBL_54_21

Get Permissions


How to cite this article:
Bakshi SS, Das S. Ototoxicity of chloroquine and hydroxychloroquine: Need for awareness during COVID-19 pandemic. Med J Babylon 2021;18:441-2

How to cite this URL:
Bakshi SS, Das S. Ototoxicity of chloroquine and hydroxychloroquine: Need for awareness during COVID-19 pandemic. Med J Babylon [serial online] 2021 [cited 2022 Jan 24];18:441-2. Available from: https://www.medjbabylon.org/text.asp?2021/18/4/441/332756



Dear Editor,

The debate on the efficacy of chloroquine (CQ) and hydroxychloroquine (HCQ) in the present severe acute respiratory syndrome coronavirus 2 (SARS COV-2) pandemic is still raging. Nevertheless, many organizations, politicians, and health-care professionals have propagated their use in prophylaxis and treatment of the infection resulting in many patients self-medicating and an increase in the demand for these drugs globally. Both these drugs are derivative of quinine, which is already known to be ototoxic.[1] Although there are no randomized trials, a substantial number of reports exist in the literature regarding the ototoxic potential of these drugs.

The ototoxicity related to CQ has been reported as early as 1968.[2] The symptoms experienced by the patient ranges from mild-to-severe sensorineural hearing loss, tinnitus, and even vestibular paresis.[3] The hearing loss can be both reversible and irreversible.[3] In addition to multiple case reports, over 700 adverse events linked to the ear and labyrinthine structure in the United States in the last 5 years were reported due to HCQ.[4]

A recent study by Mustafa et al.[5] found a significant decrease in pure tone audiometry thresholds at 4000, 6000, and 8000 Hz and transient evoked otoacoustic emissions in asymptomatic COVID-19 polymerase chain reaction (PCR)-positive cases, implying possible inner ear damage due to the infection.

The mechanism of the ototoxicity is poorly understood, and the possible hypothesizes are as follows:[1]

  1. CQ gets accumulated in the inner ear tissues containing melanin leading to vascular injury and degenerative changes in the planum semilunatum and stria vascularis.


  2. Another theory postulates that the drug may increase extracellular glutamate concentration leading to neuronal excitotoxicity. An overproduction of reactive oxygen species results in damage to the glial cells.


  3. Drug-induced vasoconstriction leading to ischemic damage to the inner ear


Many aspects regarding ototoxicity remain unclear; for example, the reported ototoxic side effects of HCQ can be due to underlying conditions like SLE. In addition, the dose of these drugs which can cause ototoxicity is unclear. However, as the ototoxic potential still exists we recommend the following:

  1. Patients on CQ or HCQ should be aware of the ototoxic potential of these drugs. They should be encouraged to report symptoms such as tinnitus imbalance and formal hearing evaluation should be done for these patients.


  2. Ongoing and future clinical trials on CQ and HCQ should monitor patients for potential ototoxicity.


  3. Patients who are self-administering these drugs can be educated and self-monitor their hearing with widely available validated free mobile applications.


  4. Other ototoxic drugs such as azithromycin and aminoglycosides should be avoided, whereas patients are on CQ and HCQ


  5. These drugs should not be used in patients with previous sensorineural hearing loss or vestibular disorders.


  6. Health-care professionals should be made aware of the ototoxic potential and early referral to an otolaryngologist should be encouraged.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
De Luca P, Scarpa A, De Bonis E, Cavaliere M, Viola P, Gioacchini FM, et al. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-cov-2 treatment: A brief review of the literature. Am J Otolaryngol 2021;42:102640.  Back to cited text no. 1
    
2.
Matz GJ, Naunton RF. Ototoxicity of chloroquine. Arch Otolaryngol 1968;88:370-2.  Back to cited text no. 2
    
3.
Mukherjee DK. Chloroquine ototoxicity—a reversible phenomenon?. J Laryngol Otol 1979;93:809-15.  Back to cited text no. 3
    
4.
U.S. Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard [WWW Document]; 2019. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/59a37af8-d2bb-4dee-90bf-6620b1d5542f/state/analysis. [Last accessed on 2021 Aug 27].  Back to cited text no. 4
    
5.
Mustafa MWM. Audiological profile of asymptomatic COVID-19 PCR-positive cases. Am J Otolaryngol 2020;41:102483.  Back to cited text no. 5
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed72    
    Printed2    
    Emailed0    
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal